Literature DB >> 10600853

Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats.

C Tschöpe1, A Reinecke, U Seidl, M Yu, V Gavriluk, U Riester, P Gohlke, K Graf, M Bader, U Hilgenfeldt, J B Pesquero, E Ritz, T Unger.   

Abstract

A reduction of renal kallikrein has been found in non-insulin-treated diabetic individuals, suggesting that an impaired renal kallikrein-kinin system (KKS) contributes to the development of diabetic nephropathy. We analyzed relevant components of the renal KKS in non-insulin-treated streptozotocin (STZ)-induced diabetic rats. Twelve weeks after a single injection of STZ, rats were normotensive and displayed hyperglycemia, polyuria, proteinuria, and reduced glomerular filtration rate. Blood bradykinin (BK) levels and prekallikrein activity were significantly increased compared with controls. Renal kallikrein activity was reduced by 70%, whereas urinary BK levels were increased up to threefold. Renal kininases were decreased as indicated by a 3-fold reduction in renal angiotensin-converting enzyme activity and a 1.8-fold reduction in renal expression of neutral endopeptidase 24.11. Renal cortical expression of kininogen and B2 receptors was enhanced to 1.4 and 1. 8-fold, respectively. Our data suggest that increased urinary BK levels found in severely hyperglycemic STZ-diabetic rats are related to increased filtration of components of the plasma KKS and/or renal kininogen synthesis in combination with decreased renal kinin-degrading activity. Thus, despite reduced renal kallikrein synthesis, renal KKS is activated in the advanced stage of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10600853     DOI: 10.1152/ajpheart.1999.277.6.H2333

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5'-monophosphate-activated protein kinase signaling pathways.

Authors:  Gang Yuan; Juanjuan Deng; Tao Wang; Chunxia Zhao; Xizheng Xu; Peihua Wang; James W Voltz; Matthew L Edin; Xiao Xiao; Lee Chao; Julie Chao; Xin A Zhang; Darryl C Zeldin; Dao Wen Wang
Journal:  Endocrinology       Date:  2007-02-01       Impact factor: 4.736

Review 2.  The role of the renal kallikrein-kinin system in diabetic nephropathy.

Authors:  Alexander Riad; Jia Long Zhuo; Heinz Peter Schultheiss; Carsten Tschöpe
Journal:  Curr Opin Nephrol Hypertens       Date:  2007-01       Impact factor: 2.894

Review 3.  The kinin system in hypertensive pathophysiology.

Authors:  Jagdish N Sharma
Journal:  Inflammopharmacology       Date:  2012-04-17       Impact factor: 4.473

4.  Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent.

Authors:  Stefan Schäfer; Hans-Ludwig Schmidts; Markus Bleich; Andreas E Busch; Wolfgang Linz
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

5.  Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy.

Authors:  S Van Linthout; A Riad; N Dhayat; F Spillmann; J Du; S Dhayat; D Westermann; D Hilfiker-Kleiner; M Noutsias; U Laufs; H-P Schultheiss; C Tschöpe
Journal:  Diabetologia       Date:  2007-06-23       Impact factor: 10.122

6.  Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats.

Authors:  Allen Clermont; Tamie J Chilcote; Takeshi Kita; Jia Liu; Priscilla Riva; Sukanto Sinha; Edward P Feener
Journal:  Diabetes       Date:  2011-03-28       Impact factor: 9.461

7.  Renal kallikrein activation and renoprotection after dual blockade of renin-angiotensin system in diet-induced diabetic nephropathy.

Authors:  Xia Zou; Xiao-xi Zhang; Xin-yu Liu; Rong Li; Min Wang; Wei-jie Wu; Yi Sui; Hai-lu Zhao
Journal:  J Diabetes Res       Date:  2015-03-30       Impact factor: 4.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.